CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 4, 2019--
Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing
novel medicines to treat life-altering central nervous system (CNS)
disorders, today announced that the Company will present at the Goldman
Sachs 40th Annual Global Healthcare Conference on Tuesday,
June 11, 2019 at 8:00 a.m. PDT (11:00 a.m. EDT) in Palos Verdes, Cal.
A live webcast of the presentation can be accessed on the investor page
of Sage's website at investor.sagerx.com. A replay of the webcast will
also be archived for up to 30 days on Sage's website following the
conference.
About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company committed to developing
novel medicines to transform the lives of patients with life-altering
central nervous system (CNS) disorders. Sage’s portfolio of novel
compounds targets critical receptor systems in the brain and includes
the first treatment specifically approved by the U.S. Food and Drug
Administration for postpartum depression as well as compounds being
developed as potential treatments for diseases such as major depressive
disorder, insomnia, bipolar disorder and essential tremor. For more
information, please visit www.sagerx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604005130/en/
Source: Sage Therapeutics
Investor Contact:
Maren Killackey, 617-949-4113
maren.killackey@sagerx.com
Media
Contact:
Jeff Boyle, 617-949-4256
jeff.boyle@sagerx.com
